At ADLM, Lipoprotein(a), Measles, and More

Why It Matters

Universal Lp(a) screening will dramatically increase test volumes and demand standardized assays, while advanced measles PCR and refined pediatric intervals enhance outbreak response and pediatric care. Together they drive operational, regulatory, and financial shifts for labs nationwide.

Key Takeaways

• ACC/AHA now recommend one‑time Lp(a) test for all adults
• Phase‑III Lp(a)‑lowering drugs aim 80‑95% reduction
• Labs must prepare for surge in Lp(a) orders and assay bias
• ARUP’s measles PCR distinguishes wild‑type from vaccine strains
• CALIPER pediatric intervals improve diagnosis for neonates and children

Pulse Analysis

The push toward universal lipoprotein(a) screening marks a watershed moment for cardiovascular risk assessment. Recent endorsements from the National Lipid Association, ACC, and AHA align with global recommendations, positioning Lp(a) as a routine component of adult health records. This policy shift forces laboratories to confront legacy assay variability, calibrator bias, and the looming shortage of reference materials. IFCC’s new mass‑spectrometry reference procedure offers a pathway to harmonization, but widespread adoption will require coordinated vendor updates and staff training.

Simultaneously, the pipeline of Lp(a)-lowering therapeutics is reaching a critical juncture. Phase‑three trials slated for late 2026 anticipate unprecedented reductions—up to 95%—that could redefine treatment algorithms for patients with genetically elevated Lp(a). Such efficacy will amplify the clinical relevance of precise measurement, compelling labs to adopt molar‑based reporting and to anticipate higher test volumes. Institutions that already run in‑house Lp(a) assays should scale reagent inventories, while those relying on reference labs must verify capacity and turnaround times to meet clinician expectations.

Beyond lipidology, the ADLM agenda spotlights the resurgence of measles and the need for robust molecular diagnostics. ARUP’s real‑time PCR on the Hologic Panther Fusion platform can differentiate wild‑type from vaccine strains, reducing false‑positive public‑health alerts and enabling faster outbreak containment. Coupled with emerging pediatric reference‑interval projects like CALIPER, these innovations underscore a broader trend: laboratories are becoming central to both chronic disease management and acute public‑health responses. Embracing standardized methods, expanding assay menus, and leveraging data‑sharing networks will be essential for labs to stay ahead in this evolving landscape.